

LIVESTREAM SESSION

10 Rechallenge



MODERATOR

Thomas Powles, MBBS, MRCP, MD
University of London
and Barts Cancer Centre



Brian Rini, MD
Vanderbilt-Ingram Cancer Center



Tian Zhang, MD
UT Southwestern
Medical Center




Toni Choueiri, MD
Dana-Farber/Harvard
Cancer Center




David McDermott, MD
Beth Israel Deaconess
Medical Center

CONTACT-03



	Atezo + Cabo (n=259)	Cabo (n=254)
ORR	41%	41%
CR	0%	2%
PR	41%	40%
SD	51%	48%
PD	4%	5%
Median DOR (mos)	12.7	14.8

TiNivo-2



	Tivo + Nivo (n=171)	Tivozanib (n=172)
ORR	19%	20%
CR	0.6%	0.6%
PR	19%	19%
SD	43%	47%
PD	29%	25%
Median DOR (mos)	15.8	9.7

Do We Need To Do This Trial?



Toni Choueiri, MD

@DrChoueiri

POLL of the Day: after Tinivo-2 and CONTACT-3 results from [#ESMO2024](#) / [#ASCO2013](#) and [@TheLancet](#) papers (PD1/L1 with atezo/nivo rechallenge in metastatic renal cancer), would you design a RDT to address Pembro rechallenge ?

YES I would

21.6%

NO-case closed

78.4%

Metastatic
months a
adjuvant

IRR

INV

olerability

Audience Question

Would you do a trial of PD(x)-based therapy in RCC after prior adjuvant Pembro?

1. Yes
2. No

Audience Question

If you did a trial, what would be the minimum time since end of Pembro?

1. 3 months
2. 6 months
3. 12 months
4. >12 months
5. Infinity, because I would never do such a trial

Would you give PD-1-based immune therapy after adjuvant pembro in RCC?

Nephrectomy

Adjuvant pembrolizumab

Months

0 3 6 9 12 18 24 36

Early
Relapse

Later
Relapse

Relapse within 1 year of stopping
pembrolizumab

Relapse >1yr since
pembrolizumab

Period 1

Period 2

Period 3

Period 4

Yes / No

Yes / No

Yes / No

Yes / No

What Is the Role of Ipilimumab Salvage in RCC?

	HCRN ¹	OMNIVORE ²	TITAN RCC ³		FRACTION ⁴	CCF ⁵
N	35	57	49		46	45
Timing	Nivo > Ipi (SD/PD ≤48 weeks)	Nivo > Ipi (SD/PD ≤6 months)	Nivo > Ipi (SD/PD week 8 or 16)		Nivo+Ipi in IO-refractory	Nivo+Ipi in IO-refractory
# of Ipi doses	4	2	2-4		4	4
ORR	11%	4%	14%		17%	20%
Primary PD	63%	40%	67%		30%	62%
CR	3%	0%	2%		0%	0%

1. Atkins M et al. JCO 2022 2. McKay et al. JCO 2020 3. Grimm et al. ESMO 2022 4. Choueiri et al. JITC 2022 5. Gul et al. JCO 2020

Audience Question

Overall, which regimen would you give to the majority of IO-refractory RCC?

1. IO/TKI
2. Ipi/Nivo
3. Single agent TKI

KCCure Survey 2024: 843 total responses, 322 pts report getting systemic therapy

- 115 of 232 (49.5%) pts treated with first-line combination IO/IO or IO/TKI reported getting treated with second-line therapy.
- Of the 115 pts, 25 (**22%**) reported being treated with immunotherapy in the second line.
 - 11 pts got IO/TKI following ipi/nivo
 - 5 pts got ipi/nivo following IO/TKI
 - 7 pts got IO/TKI followed by IO/TKI
 - 2 pts got nivo monotherapy following len/pem and axi/pem

Patient Survey 2024



Share your voice!
Help improve care

